COVID-19 Cases Have Surpassed 250 Million Worldwide
2 Min Read
COVID-19 cases are on the rise globally, Eastern Europe takes the bulk of the burden.
-
A medic tends to patients with coronavirus disease (COVID-19) in the Pirogov hospital's intensive care unit (ICU) in Sofia, Bulgaria, October 15, 2021. Stoyan Nenov/REUTERS
On Monday, COVID-19 number of Global cases surpasses 250 million amid a surge in Eastern European Countries, despite the fact that the Delta variant surge has subsided and several countries have resumed trade and tourism, as reported by Reuters.
According to another Reuters study, the daily average number of infections has dropped by 36% in the last three months, but the virus still infects 50 million individuals every 90 days due to the highly transmissible Delta form.
The first 50 million COVID-19 cases, on the other hand, took nearly a year to document.
Health experts are optimistic that because of the immunization and natural exposure processes, many countries have overcome the worst of the pandemic, though they warn that colder weather and forthcoming holiday festivities may increase infections, according to Reuters.
The Eastern Europe Case
Eastern Europe has some of the region's lowest vaccination rates. According to the data cited by Reuters, Europe accounted for more than half of all new cases recorded worldwide, with a million new infections reported every four days.
As the country observes record deaths due to the illness, several Russian regions announced this week that they may impose new restrictions or extend a working closure.
COVID-19 treatments are coming out
Various pharma companies around the world started delivering COVID-19 treatment as of the beginning of this month. On November 5th, Pfizer had announced, that its antiviral COVID-19 pill cut the risk of hospitalization or death by 89% in virus patients.
The preliminary results from the trial were so positive that an independent board of experts recommended discontinuing the tests so that the drug be offered to the public, the drugmaker said.
On another occasion, On November 4th, British regulators approved the experimental drug Molnupiravir from US pharmaceutical giant Merck, marking the first time an oral antiviral treatment for Covid-19 in adults has been approved by a public health body.
